Cheryl ArrowsmithProfile page
Professor
Temerty Faculty of Medicine, Department of Medical Biophysics
- ProfessorTemerty Faculty of Medicine, Department of Medical Biophysics
- (416) 946-0881
- Structural Genomics Consortium, 101 College Street, 7-707, Toronto, Ontario, M5G 1L7, Canada
BIO
Dr. Arrowsmith received her Ph.D. in chemistry from the University of Toronto and carried out postdoctoral research at Stanford University. She is the director of the Toronto Node of the Structural Genomics Consortium (SGC), Senior Scientist at the Princess Margaret Cancer Centre, and Professor of Medical Biophysics at the University of Toronto. Dr. Arrowsmith is an internationally recognized expert in cancer related structural biology & chemical biology and epigenetics. She has been the leader of the Toronto site of the SGC since its inception and coordinates the SGC’s epigenetic chemical probe program. Dr. Arrowsmith was co-founder of Affinium Pharmaceuticals, a structure-based biotech that developed an anti-MRSA antibiotic that recently completed successful phase IIa trials. She has served as a member of 18 scientific advisory boards, grant review panels and journal editorial boards since 2000, including current membership on the Board of Directors of Academic Drug Discovery Consortium (ADDC). Dr. Arrowsmith holds a Canada Research Chair in Structural Genomics at the University of Toronto, has published over 250 peer reviewed articles, with more than 60 of these published in the last 5 years, and is co-author of over 1800 3D protein structures in the Protein DataBank (PDB). Her current research focuses on structural biology and chemical biology approaches to understand how transcriptional and chromatin regulatory proteins recognize, interact with and signal to other molecular components of the cell.
At A Glance:
- We are an interdisciplinary lab studying the structure, function and chemical modulation of proteins involved in epigenetics and nuclear signalling – cellular mechanisms that are disrupted in cancer and other diseases.
- We use structural biology and chemical biology approaches to understand how transcriptional and chromatin regulatory proteins recognize, interact with and signal to other molecular components of the cell.
- In conjunction with the Structural Genomics Consortium (SGC), we are using our protein structural information to develop new chemical genetic tools to define, perturb and manipulate essential functions of proteins involved in methylation dependent signalling.
DEGREES
- PhDUniversity of Toronto, Toronto, Canada
INSTITUTIONAL STRATEGIC INITIATIVES
- Acceleration Consortium
- MITO2i (Mitochondrial Innovation Initiative)
- PRiME (Precision Medicine Initiative)
- EPIC (Emerging and Pandemic Infections Consortium)
AFFILIATED INSTITUTIONS
- University Health Network